GSK Paxil CR PMDD approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
GlaxoSmithKline's selective serotonin reuptake inhibitor Paxil CR (paroxetine) clears FDA Aug. 28 for treatment of premenstrual dysphoric disorder, becoming the first controlled release antidepressant approved for PMDD. The other two approved PMDD therapies, Pfizer's Zoloft (sertraline) and Lilly's Sarafem (fluoxetine), are immediate release SSRI products. Paxil CR may have a dosing advantage over Zoloft, which can require titration when used for PMDD (1Pharmaceutical Approvals Monthly July 1, 2003, p. 11). The CR approval comes soon after the introduction of generic competition to immediate release Paxil; FDA cleared Apotex subsidiary TorPharm's generic version of IR Paxil July 30, but at least three other firms will share exclusivity. Synthon's mesylate-based formulation of paroxetine cleared FDA July 3 as a 505(b)2 NDA and will launch in the fourth quarter...
You may also be interested in...
Paxil CR For PMDD: FDA Decision Expected In “Coming Months,” GSK Says
GlaxoSmithKline expects to hear from FDA “in the coming months” on a pending premenstrual dysphoric disorder indication for its antidepressant Paxil CR.
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.